
Collegium Pharmaceutical (COLL) Stock Forecast & Price Target
Collegium Pharmaceutical (COLL) Analyst Ratings
Bulls say
Collegium Pharmaceutical Inc. has demonstrated robust growth, with a 31% year-over-year increase in net revenue to $209.4 million, surpassing both forecast expectations and consensus estimates. The company's flagship product, Jornay, continues to excel, showing a 20% increase in total prescriptions year-over-year and a notable sequential revenue growth of 28.2%, supported by an improvement in gross-to-net ratios. Furthermore, the positive revisions to 2025 guidance, including raised top-line expectations to $745 million-$760 million and solid contributions from the adult segment, underscore strong market positioning and potential for sustained expansion.
Bears say
Collegium Pharmaceutical Inc. has highlighted several vital concerns that contribute to a negative outlook on its stock, such as a reduction in prescriptions for key products like Xtampza ER and Nucynta, as well as lower sales projections linked to the potential entry of generic competitors. Although operating cash flow reached $78.4 million for the quarter and net leverage improved to approximately 1.2x adjusted EBITDA, risks persist regarding commercialization delays and higher-than-expected expenses, which might hinder profit margins. Additionally, management's goals to reduce net leverage below 1.0x by the end of 2025 could face challenges due to unfavorable reimbursement landscapes and execution risks related to product integration and regulatory compliance.
This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Collegium Pharmaceutical (COLL) Analyst Forecast & Price Prediction
Start investing in Collegium Pharmaceutical (COLL)
Order type
Buy in
Order amount
Est. shares
0 shares